Ignite Creation Date:
2024-05-06 @ 2:41 AM
Last Modification Date:
2024-10-26 @ 11:22 AM
Study NCT ID:
NCT02103959
Status:
COMPLETED
Last Update Posted:
2016-02-23
First Post:
2014-04-01
Brief Title:
Safety and Efficacy of CMX-2043 for Protection of the Heart and Kidneys in Subjects Undergoing Coronary Angiography
Sponsor:
Ischemix LLC
Organization:
Ischemix LLC
Study Overview
Official Title:
A Prospective Comparative Randomized Multi-Center Double-Blinded Placebo-Controlled Phase 2a Study of the Safety and Efficacy of CMX-2043 for Periprocedural Injury Protection in Subjects Undergoing Coronary Angiography at Risk of Radio-contrast Induced Nephropathy CARIN
Status:
COMPLETED
Status Verified Date:
2014-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CARIN
Brief Summary:
The objective of this study is to evaluate CMX-2043 for prevention of renal and cardiac injury associated with coronary angiography in patients with acute coronary syndrome ACS but excluding ST-elevation myocardial infarction STEMI patients This study will specifically examine the ability of CMX-2043 to prevent acute renal injury following coronary angiography The study will also examine the ability of CMX 2043 for prevention of periprocedural cardiac injury Information will be obtained relating to the ability of CMX 2043 for prevention of major adverse cardiac and renal events following the procedure Additional information will be obtained in this study to evaluate safety of the drug Dose and regimen information will also be obtained for future clinical studies of CMX-2043
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None